BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T135922
CREATED:20240719T112018Z
LAST-MODIFIED:20240722T133910Z
UID:39410-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:2nd Covalent Drug Discovery & Development Summit
DESCRIPTION:Discover & Develop Selective\, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology\, Immunology & Beyond \nThe covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology\, immunology and CNS. Yet\, key challenges remain in balancing reactivity and sensitivity\, de-risking the ligandability of alternative residues\, and tackling PKPD disconnects and efficiency bottlenecks\, \nBringing together 100+ covalency experts\, the 2nd Covalent Drug Discovery & Development Summit returns as the only dedicated forum to comprehensively cover discovery to translation and clinical development of covalent therapeutics. \n\nDates: December 10-12\, 2024\nLocation: Hilton Boston Logan Airport\, Boston\, Massachusetts\nEvent Program: https://ter.li/bz5jjg\n\nDive into extensive technical content spanning target selectivity\, hit screening\, lead optimization and covalent warhead design\, network with over 100 heads\, directors and VPs of Proteomics\, Medicinal Chemistry\, Chemical Biology\, Discovery Biology and Pharmacology\, and hear from the brightest minds of academia as they share their latest findings. \nDownload the program here: https://ter.li/bz5jjg \nRegister your place here (and take advantage of group discounts of up to 20% when registering your team of two or more!): https://ter.li/8257lj
URL:http://www.pharmajournalist.com/event/2nd-covalent-drug-discovery-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T135922
CREATED:20240828T105923Z
LAST-MODIFIED:20240828T105923Z
UID:39639-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:With recent accelerated approval wins\, positive clinical trial readouts\, progression through clinical pipelines and exciting mergers and acquisitions\, it has certainly been an industry-defining year for the rare and genetic renal space. \nIn the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients\, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry\, academic KOL\, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations. \nJoin Mironid\, AstraZeneca\, Novartis\, Maza Therapeutics\, Harvard Medical School\, and more as you dive into critical topics investigating IgAN\, FSGS\, PKD\, Alport Syndrome and more therapeutic areas to foster partnerships and accelerate game-changing therapies into the clinic and to rare renal diseases patients in need. \nView the full event program here: https://ter.li/ncjxqh
URL:http://www.pharmajournalist.com/event/4th-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T135922
CREATED:20240828T110543Z
LAST-MODIFIED:20240828T110543Z
UID:39644-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:7th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus\, there have been many valuable collaborations entering the RNA-targeting field\, accelerating efficacious and selective small molecules targeting RNA directly\, RNA-binding proteins\, and RNA/protein complexes. \nHence\, as the go-to meeting for the RNA-targeting small molecule community\, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures\, delve into innovative preclinical modeling strategies\, and identify optimal chemical features for advancing specific\, efficacious\, and safe small molecules. \nCurated in collaboration with large pharma\, innovative biotech\, and leading academics\, the 7th RNA-Targeted Drug Discovery & Development Summit returns with 3 jam-packed days and unrivaled networking opportunities with the key stakeholders to accelerate the discovery of disease-relevant RNA\, optimize small molecule design\, and uncover novel targets on proteins\, enzymes\, and RNA/protein complexes to increase the landscape of treatable diseases. \nUnite with 100+ RNA Science\, Medicinal Chemistry\, Structural Biology & Biophysics experts from the likes of AstraZeneca\, Sanofi\, Novartis\, PTC Therapeutics\, ReviR Therapeutics\, Rgenta Therapeutics\, Accent Therapeutics\, and more at the most comprehensive and definitive event for the community\, the 7th RNA-Targeted Drug Discovery & Development Summit\, to accomplish faster and smoother translation of RNA-targeted therapies towards the clinic. \nTo know more visit: www.rna-drugdiscovery.com
URL:http://www.pharmajournalist.com/event/7th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T135922
CREATED:20240904T120903Z
LAST-MODIFIED:20240904T120903Z
UID:39686-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:8th Complement-Based Drug Development Summit
DESCRIPTION:With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH\, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? \nWith assets in nephrology\, ophthalmology\, neurodegeneration\, and inflammation all progressing through to the clinic\, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies. \nJoin 100+ industry leaders\, scientists\, and clinicians at the premier\, end-to-end\, 8th Complement-Based Drug Development Summit to shape the future of complementtargeted therapies. Across 3 days of content\, you can expect discussions spanning: \n\nStrategic targeting and preclinical breakthroughs for the next-generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets\nNavigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication\nExploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort\nMoving from targeting rare disease with complement inhibitors to larger patient populations\nNavigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster\n\nKey benefits of attending: \n\nDelve into the pathophysiology of different complement pathways for the specific targeting of acute and chronic inflammatory diseases with Apterion Therapeutics\, Annexon Bio\,and Sanofi to determine the most effective pathway when developing complement inhibitors\nExplore the potential for combination therapies with existing complement therapies and other modalities with CSL Behring for a more precise approach to hit inflammation and autoimmune diseases harder beyond complete immunosuppressive approaches.\nDiscuss the move from targeting rare diseases with complement inhibitors to more common diseases with IgM Biosciences\, Grid Therapeutics\,and Astellas\, to target larger patient populations\nEvaluate the value proposition of targeting complement proteins with advanced therapeutics such as RNAi and gene therapies to determine the optimal mode of action and make complement inhibitors more targeted with Beacon Therapeutics and Arrowhead Pharmaceuticals\n8 Brand New Data readouts focusing on the translational and clinical stages of complement inhibitor development to help you stay up to date as this field makes strides towards regulatory approval
URL:http://www.pharmajournalist.com/event/8th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T135922
CREATED:20240930T131805Z
LAST-MODIFIED:20240930T131943Z
UID:39832-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th ADC Target Selection Summit
DESCRIPTION:The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs. \nWith sessions led by Almac Discovery\, AstraZeneca\, Bolt Biotherapeutics\, and many other industry leaders\, leave this meeting equipped to perform a strategic evaluation of when and how to approach developing an ADC against a novel target. Enhance this knowledge with exclusive insight from brand-new biotechs\, Epifold and GO Therapeutics striving to leave their mark on the ADC field by sharing their innovative strategy which has reaped success in novel ADC targeting. \nDon’t miss this opportunity to join an audience of 80+ highly focused biologists\, discovery researchers\, computational biologists and bioinformaticians\, as well as senior C-level and Alliance Management experts. End your 2024 ADC conference calendar with the perfect balance of scientific and strategic level conversations and gain the know-how to invigorate your target selection strategy and propel more ADCs to first-in-class therapeutics. \nView all the industry strategies\, innovation sessions and networking opportunities in the FREE event guide here: https://ter.li/un31n9
URL:http://www.pharmajournalist.com/event/4th-adc-target-selection-summit/
LOCATION:DoubleTree by Hilton Hotel\, San Diego Downtown\, 1646 Front Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T135922
CREATED:20241114T161818Z
LAST-MODIFIED:20241114T161908Z
UID:40104-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:The 4th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Join industry leaders like Eli Lilly\, Merck\, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12\, 2024 – Philadelphia\, PA). This is your perfect moment to network with enzyme discovery\, engineering\, biocatalysis\, and process chemistry professionals from both industry and academia. \nCapitalize on Enzyme Evolution through HTP Screening\, Advanced Engineering & Deploy Maturing Biocatalysis Techniques in Small Molecules & Complex Modalities. \nNow with a sharper focus on enzyme engineering and expanded coverage of biocatalysis-derived oligonucleotides\, peptides and other large biologics. Plus\, dive into brand-new biopharma case studies designed to boost enzyme efficiency and therapeutic yields. \nWhy Attend? \n– Revolutionize Biologics Development: Discover cutting-edge oligonucleotide production case studies that are setting new standards in biologics \n– Streamline Enzyme Discovery: Learn how to prioritize and engineer enzymes from early-stage proof of concept to accelerate your pipeline \n– Fast-Track Decision Making: Master modern prediction methods and sophisticated high-throughput techniques to refine enzyme selection \n– Optimize Small Molecule Biocatalysis: Gain insights from pharma-led projects focused on enhancing activity\, yields and green chemistry \nWhat to Expect? \n– Exclusive interactive discussions exploring ML-informed enzyme design techniques \n– Poster session opportunity to showcase your current work and gain feedback from 60+ senior peers \n– 20+ industry speakers to inspire you and help you take advantage of biocatalysis in its prime \n– Pharma and academia-led workshops to perfect enzyme decision-making and late process optimization \nLet’s innovate and elevate drug development pipelines together through the power of green biocatalysis. \nTo know more visit: https://ter.li/t9gd14
URL:http://www.pharmajournalist.com/event/the-4th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR